Colinz Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Colinz Laboratories Ltd is ₹ 46.1 as of 30 Apr 15:30 . The P/E Ratio of Colinz Laboratories Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Colinz Laboratories Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Colinz Laboratories Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Colinz Laboratories Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Colinz Laboratories Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Colinz Laboratories Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Colinz Laboratories Ltd

Colinz Laboratories Limited, was incorporated as a Private Limited Company in 1986.
The Company got converted into Public Limited Company in 1995, which however started their manufacturing and marketing activities in 1995.
The Company manufactures a wide variety of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams etc.
The Company is having certain specialized products for Gynaecology, Cardiology, Gastroentrology etc.
Since, the Company falls under the MSME sector, it established reputation as a quality supplier of medicines in the domestic market, wherever the Company has operation. Apart from this, the Company has a WHO compliant plant at Sinnar.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Colinz Laboratories Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Colinz Laboratories Ltd or Sanofi India Ltd?

Market cap of Colinz Laboratories Ltd is 5 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Colinz Laboratories Ltd and Sanofi India Ltd?

The stock performance of Colinz Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Colinz Laboratories Ltd and Sanofi India Ltd?

As of May 4, 2026, the Colinz Laboratories Ltd stock price is INR ₹46.1. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Colinz Laboratories Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Colinz Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.